Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 2;12(7):e0070424.
doi: 10.1128/spectrum.00704-24. Epub 2024 Jun 11.

Impact of extended-spectrum chromosomal AmpC (ESAC) of Escherichia coli on susceptibility to cefiderocol

Otávio Hallal Ferreira Raro  1 , Christophe Le Terrier  1   2 , Patrice Nordmann  1   3 , Laurent Poirel  1   3
Affiliations

Impact of extended-spectrum chromosomal AmpC (ESAC) of Escherichia coli on susceptibility to cefiderocol

Otávio Hallal Ferreira Raro et al. Microbiol Spectr. .

Abstract

The impact of chromosomally encoded wild-type or extended-spectrum (ESAC) AmpC β-lactamases of Escherichia coli on susceptibility to ceftazidime, cefepime, and cefiderocol was evaluated in different genetic backgrounds, including wild-type, PBP3-modified, and porin-deficient E. coli strains. Recombinant E. coli strains possessing the different backgrounds and producing variable ESACs were evaluated. Although ESAC enzymes conferred resistance to ceftazidime and decreased susceptibility to cefepime as expected, we showed here that cefiderocol was also a substrate of ESAC enzymes.

Importance: We showed here that chromosomally encoded intrinsic extended-spectrum cephalosporinases of Escherichia coli may impact susceptibility not only to ceftazidime and cefepime but also to cefiderocol.

Keywords: AmpC; ESAC; Escherichia coli; cefiderocol.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Kaper JB, Nataro JP, Mobley HL. 2004. Pathogenic Escherichia coli. Nat Rev Microbiol 2:123–140. doi:10.1038/nrmicro818 - DOI - PubMed
    1. Pitout JDD. 2012. Extraintestinal pathogenic Escherichia coli: a combination of virulence with antibiotic resistance. Front Microbiol 3:9. doi:10.3389/fmicb.2012.00009 - DOI - PMC - PubMed
    1. Jacoby GA. 2009. AmpC β-lactamases. Clin Microbiol Rev 22:161–182. doi:10.1128/CMR.00036-08 - DOI - PMC - PubMed
    1. Coolen JPM, den Drijver EPM, Kluytmans JAJW, Verweij JJ, Lamberts BA, Soer JACJ, Verhulst C, Wertheim HFL, Kolwijck E. 2019. Development of an algorithm to discriminate between plasmid- and chromosomal-mediated AmpC β-lactamase production in Escherichia coli by elaborate phenotypic and genotypic characterization. J Antimicrob Chemother 74:3481–3488. doi:10.1093/jac/dkz362 - DOI - PMC - PubMed
    1. Kawamura M, Ito R, Tamura Y, Takahashi M, Umenai M, Chiba Y, Sato T, Fujimura S. 2022. Overproduction of chromosomal ampC β-lactamase gene maintains resistance to cefazolin in Escherichia coli isolates. Microbiol Spectr 10:e0005822. doi:10.1128/spectrum.00058-22 - DOI - PMC - PubMed

MeSH terms

Grants and funding

LinkOut - more resources